Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Deferred Taxes (2019 - 2021)

Amphastar Pharmaceuticals (AMPH) has 5 years of Deferred Taxes data on record, last reported at $2.8 million in Q4 2021.

  • For Q4 2021, Deferred Taxes fell 26.79% year-over-year to $2.8 million; the TTM value through Dec 2021 reached $4.6 million, up 2728.4%, while the annual FY2025 figure was -$28.7 million, 260.36% down from the prior year.
  • Deferred Taxes reached $2.8 million in Q4 2021 per AMPH's latest filing, down from $3.8 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $5.3 million in Q4 2019 and bottomed at -$2.0 million in Q3 2020.
  • Average Deferred Taxes over 3 years is $1.7 million, with a median of $2.8 million recorded in 2021.
  • Peak YoY movement for Deferred Taxes: decreased 28.71% in 2020, then decreased 26.79% in 2021.
  • A 3-year view of Deferred Taxes shows it stood at $5.3 million in 2019, then fell by 28.71% to $3.8 million in 2020, then decreased by 26.79% to $2.8 million in 2021.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were $2.8 million in Q4 2021, $3.8 million in Q4 2020, and -$2.0 million in Q3 2020.